{
    "clinical_study": {
        "@rank": "80630", 
        "arm_group": [
            {
                "arm_group_label": "PPI-383 single dose escalation in healthy volunteers", 
                "arm_group_type": "Experimental", 
                "description": "There will be up to 10 sequential single dose cohorts to assess the bioavailability of different doses and formulations;  a food effect cohort will be included."
            }, 
            {
                "arm_group_label": "PPI-383 multiple doses in healthy volunteers", 
                "arm_group_type": "Experimental", 
                "description": "Upon completion of the single dose cohorts, an additional cohort will receive the highest well-tolerated dose from the single dose cohorts or placebo once daily for five days;  up to 2 additional cohorts may receive multiple doses of different formulations or different regimens"
            }, 
            {
                "arm_group_label": "PPI-383 multiple dose escalation in HCV Subjects", 
                "arm_group_type": "Experimental", 
                "description": "Upon completion of the single and multiple dose healthy volunteer cohorts, there will be 3, and potentially 4, sequential cohorts of HCV patients"
            }
        ], 
        "brief_summary": {
            "textblock": "PPI-383 is an antiviral agent (an inhibitor of the hepatitis C virus NS5B polymerase) that\n      is being developed as a potential treatment for hepatitis C virus infection. This study is\n      being done to assess the dose-related safety and tolerance of PPI-383 when given to healthy\n      volunteers for up to 5 days (Part I of the study) and to hepatitis C patients for up to 3\n      days (Part II). In addition, the study will assess how much PPI-383 is absorbed into the\n      bloodstream. In Part II, the dose-related effect of PPI-383 on the amount of hepatitis C\n      virus in patients' bloodstream (serum HCV RNA levels) also will be assessed."
        }, 
        "brief_title": "A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Part I volunteers (single and multiple dose) - key inclusion criteria\n\n          -  Healthy males\n\n          -  Age 18 to 55 years\n\n          -  Body mass index (BMI)18 to 32 kg/m2\n\n        Part II patients- key inclusion criteria\n\n          -  Males, or females of non-childbearing potential\n\n          -  Age 18 to 65 years\n\n          -  Chronic hepatitis C, and absence of other known liver disease\n\n          -  Seropositive for HCV antibody (HCV Ab) or HCV RNA at least once previously\n\n          -  Seropositive for HCV Ab at screening\n\n          -  Serum HCV RNA > 5 log10 IU/mL at screening\n\n          -  HCV gt-1\n\n          -  Treatment-na\u00efve for hepatitis C:\n\n          -  BMI 18 to 35 kg/m2\n\n          -  Otherwise in good health, without severe or clinically significant chronic or\n             recurrent conditions requiring frequent medical intervention or continual\n             pharmacologic management, except for anti-hypertensive use\n\n          -  No medical or psychosocial conditions that would potentially interfere with the\n             subject's ability to comply with the study assessments or visit schedule.\n\n        Part II patients - key exclusion criteria\n\n          -  Seropositive for human immunodeficiency virus (HIV) antibody or hepatitis B virus\n             (HBV) surface antigen (HBsAg)\n\n          -  Signs or symptoms of decompensated liver disease\n\n          -  Evidence of cirrhosis or hepatocellular carcinoma\n\n          -  Diabetes Mellitus treated with insulin or hypoglycemic agents\n\n          -  Asthma requiring hospital admission within the preceding 12 months\n\n          -  History of alcohol abuse or illicit drug use which could interfere with a patient's\n             compliance with the protocol requirements\n\n          -  Any of the following laboratory values at screening\n\n               -  Haemoglobin (Hgb) <11 g/dL in women or 12 g/dL in men\n\n               -  White blood cell count <4,000/mm3\n\n               -  Absolute neutrophil count (ANC) < 1800 per mm3\n\n               -  Platelet count <100,000 per mm3\n\n               -  Serum creatinine > upper limit of normal (ULN) at the central study laboratory\n\n               -  Serum albumin <3.4 g/dL\n\n               -  Total bilirubin >2.0 mg/dL\n\n          -  Clinically significant abnormality in the electrocardiograms (ECGs) at screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "144", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928147", 
            "org_study_id": "PPI-383-101"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "PPI-383 single dose escalation in healthy volunteers", 
                    "PPI-383 multiple doses in healthy volunteers", 
                    "PPI-383 multiple dose escalation in HCV Subjects"
                ], 
                "intervention_name": "PPI-383", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "PPI-383 single dose escalation in healthy volunteers", 
                    "PPI-383 multiple doses in healthy volunteers", 
                    "PPI-383 multiple dose escalation in HCV Subjects"
                ], 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "NS5B polymerase inhibitor", 
            "Phase 1", 
            "Genotype 1"
        ], 
        "lastchanged_date": "August 20, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "NW3 2QG"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "W2 1NY"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "UE1 2AD"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SE5 9RS"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Lorna Patrick", 
                    "phone": "44 (0)115 931 5509"
                }, 
                "facility": {
                    "address": {
                        "city": "Nottingham", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase Ia and Ib Dose-Ranging Study to Assess the Safety, Pharmacokinetics, and Antiviral Efficacy of PPI-383 in Healthy Adults and Hepatitis C Patients", 
        "overall_contact": {
            "last_name": "Presidio Pharmaceuticals", 
            "phone": "415-655-7581"
        }, 
        "overall_official": {
            "affiliation": "Presidio Pharmaceuticals", 
            "last_name": "Nathaniel Brown, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Research Ethics Committee", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
                "France: Committee for the Protection of Personnes"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety and tolerability, as measured by clinical adverse events and laboratory assessments", 
            "safety_issue": "Yes", 
            "time_frame": "Part I, up to day 12; and Part II, up to day 17"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928147"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "PPI-383 plasma levels", 
                "safety_issue": "No", 
                "time_frame": "Part I, up to day 12; and Part II, up to day 17"
            }, 
            {
                "measure": "serum HCV RNA levels", 
                "safety_issue": "No", 
                "time_frame": "Part II, up to day 17"
            }
        ], 
        "source": "Presidio Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Presidio Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}